Medtronic bought Cardiocom for $200 million in cash in an M&A deals bid to get into the disease management business.

Cardiocom, the company that was acquired in the M&A deals, makes devices aimed at helping to manage chronic conditions like diabetes or heart disease.

Medtronic, the company that acquired Cardiocom in the M&A deals, said it expects the effect of the buyout to be neutral to fiscal 2014 earnings.

With the M&A deals acquisition of Cardiocom, Medtronic's portfolio of products and services will span the continuum of care for the management of heart failure, which affects an estimated 7.5 million people in the U.S. and is a significant burden to the healthcare system - representing 1.1 million hospital visits per year in the U.S. at a cost of $39 billion each year.

Related

Report: Cardiovascular Partnering Terms and Agreements

Report: Congestive Heart Failure Partnering

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter